



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>C12P 21/06</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/03521</b> <b>(43) International Publication Date:</b> 8 February 1996 (08.02.96)
<b>(21) International Application Number:</b> PCT/US95/08971 <b>(22) International Filing Date:</b> 21 July 1995 (21.07.95)  <b>(30) Priority Data:</b> 08/278,281 21 July 1994 (21.07.94) US Not furnished 20 July 1995 (20.07.95) US  <b>(71) Applicants:</b> YISSUM RESEARCH AND DEVELOPMENT CO. [IL/IL]; Hebrew University of Jerusalem, P.O. Box 4279, 91042 Jerusalem (IL). LASTER, Morris, C. [US/IL]; 34 Derech Haboresh, 97278 Jerusalem (IL).  <b>(72) Inventors:</b> OPPENHEIM, Amos, B.; 5 Harav Shrem Yossef Street, 96920 Jerusalem (IL). GILADI, Hilla; 25 Hashalom Street, P.O. Box 570, 97706 Mevasseret Zion (IL). GOLD-ENBERG, Daniel; 9/1 Hakinor Street, 97500 Ma'ale Adu-mimn (IL). KOB1, Simi; 1/6 Anussey Mash'had Street, East Talpiyot, 93784 Jerusalem (IL). AZAR, Idit; 5/10 Hashom-rim Street, 76232 Rehovot (IL).  <b>(74) Agents:</b> LAVALLEYE, Jean-Paul et al.; Oblon, Spivak, McClelland, Maier & Neustadt, P.C., 4th floor, Crystal Square Five, 1755 Jefferson Davis Highway, Arlington, VA 22202 (US).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> VECTORS AND TRANSFORMED HOST CELLS FOR RECOMBINANT PROTEIN PRODUCTION AT REDUCED TEMPERATURES		
<b>(57) Abstract</b>  The invention relates to an expression vector, the nucleic acid sequence of which comprises a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20 °C, the production of recombinant peptide or protein encoded by a gene contained within the vector. The invention also relates to host cells containing the vectors and to a method of producing a recombinant protein.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### Description

#### Vectors And Transformed Host Cells For Recombinant Protein Production At Reduced Temperatures

This application is a continuation in part of U.S. Serial No. 08/278,281, filed on July 21, 1994.

### Technical Field

The invention relates to an expression vector, the nucleic acid sequence of which comprises a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20°C, the production of recombinant peptide or protein encoded by a gene contained within the vector. The invention also relates to transformed host cells containing the vectors, and to a method of producing a recombinant protein.

### Background Art

Genetic engineering provides methods for the cloning of foreign genes, their cDNA sequences or portions thereof, and their introduction into bacterial host cells such as *Escherichia coli*. The level of production of a foreign protein in the host cell depends on appropriately arranged transcription and translation control sequences that permit the regulated expression of the desired proteins or peptides coded by the foreign genes, gene fragments, various gene fusions or mutants thereof.

Transcription (i.e., the process leading to the production of mRNA) is a key step in the expression of a gene. Transcription initiation occurs at specific promoters which regulate gene expression. Promoters are regulated negatively by repressors and positively by activator proteins. The initiation of transcription can be separated into several steps (Buc et al., Biochemistry (1985) 24:2712). In order to act effectively, promoters are made of three elements. A core sequence is recognized by RNA polymerase. This region is flanked by

-2-

the USB, or the upstream region, and the DSR, or the downstream region. The USB was shown to bind specific activator proteins (Adhya et al., Gene (1993) 132:1). Two modes of gene activation are generally considered. DNA-bound activator makes direct contact with RNA polymerase and thereby facilitates the binding and isomerization of RNA polymerase. Alternately, the bound activator changes the structure of the promoter, thereby favoring transcription initiation.

In order to maintain the desired foreign gene and to express it in a bacterial host cell at a high level for protein purification, it is essential to place the gene under the control of a regulated promoter that permits turning off of gene expression during the first stage of fermentation in which the cell mass is increased, and turning it on at the second fermentation stage in which maximal gene expression and protein production is needed.

Production of proteins utilizing a number of promoters and ribosome binding sites has been previously described. For example, the use of the pL promoter for regulated gene expression has been the subject of several references (e.g., Bernard et al., Gene (1970) 5:59; Derom et al., Gene (1982) 17:45; Gheysen et al., Gene (1982) 17:55; Hedgpeth et al., Mol. Gen. Genet. (1978) 163:197; Remaut et al., Gene (1981) 15:81; and Deryneck et al., Nature (1980) 287). A number of ribosome binding sites have been employed in order to obtain a high level of protein synthesis, such as the phage  $\lambda$  cII translation initiation region used for the production of cII (Oppenheim et al., J. Mol. Biol. (1982) 158:327; Shimatake et al., Nature (1981) 292:128). Similarly, production of human growth hormone (hGH) and bovine growth hormone (bGH) are described, *inter alia*, in U.S. Patent No. 4,997,916.

SUBSTITUTE SHEET (RULE 26)

One of the major problems in producing eukaryotic proteins in the bacterium *E. coli* is that the desired protein is often obtained in inactive aggregates termed inclusion bodies. The inclusion bodies can facilitate protein purification provided that it is possible to refold the desired peptide to the active protein form *in vitro* by some process (see, for example, U.S. Patent No. 4,997,916). However, there are proteins for which *in vitro* refolding is highly inefficient.

Several factors appear to contribute to the formation of inclusion bodies. The most important of these are the rapid synthesis of a single protein following induction of gene expression in the fermentation process, and the temperature at which fermentation takes place. At high temperatures, refolding of the individual molecule is slowed down. The presence of a high concentration of incompletely folded proteins leads to protein aggregation due to the inter-molecular interactions of hydrophobic domains. In production of the native protein, these hydrophobic domains play an important role in the folding of the protein into a fully active form.

At present, there is no known way to direct the production of proteins in their native form during the fermentation process. For some proteins (such as hGH and bGH) it is possible to disaggregate and refold the desired protein, while for others there is no known refolding process. However, it is known that chaperonin protein complexes can act to facilitate disaggregation *in vivo*. This process can also be carried out on a small scale in biochemical laboratories.

It has been shown that proteins expressed in *E. coli* at low temperatures have an increased solubility (Schein et al., Bio/Technology (1988) 6:291; Schein, Bio/Technology (1989) 7:1141). For example, when

-4-

interferon (IFN- $\alpha$ 2) was expressed in a bacterial culture at 37°C, 95% of the protein was found in inclusion bodies. In contrast, only 27% of the protein was insoluble when the same culture was grown at 30°C. Similar results were obtained for IFN- $\gamma$ , and Shirano et al. (FEBS (1990) 1:128) demonstrated the low-level expression of soluble lipoxxygenase in *E. coli* at about 15°C.

Accordingly, there remains a need for vectors which allow for the isolation of biologically active eukaryotic protein from bacterial cells. It is an object of the present invention to provide such vectors, as well as methods for the production and isolation of eukaryotic proteins from bacterial cells in a biologically active form. It is another object of the present invention to provide host-vector systems for the production of a desired protein in native form.

These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

#### Disclosure of the Invention

The present invention provides an expression vector, the nucleic acid sequence of which comprises a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20°C, the production of recombinant peptide or protein encoded by a gene contained within the vector.

The invention also relates to transformed host cells containing the vectors, particularly transformed *E. coli* host cells.

In addition, the invention relates to a method of producing in native active form a desired protein encoded by a gene contained within the vector.

**SUBSTITUTE SHEET (RULE 26)**

### Brief Description of the Figures

Figure 1 depicts the DNA sequence of the pL promoter region including the nucleotides flanking the Eco RI and Bam HI sites. This sequence is also set forth in SEQ ID NO:1.

Figure 2 depicts the restriction map of plasmid pHG87, which contains the wild-type pL promoter.

Figure 3 depicts the restriction map of the plasmid pHG91, which contains the mutant pL promoter pL-9G-50. The sequence of this promoter is also set forth in SEQ ID NO:2.

Figure 4 depicts (A) the presence of the mutant pL promoter pL-9G-50 in the plasmid pHG91K and its insertion into phage  $\lambda$ B299 by means of a double crossover recombination event and (B) the resulting vector  $\lambda$ lambdaA01107 ( $\lambda$ A01107).

Figure 5 depicts the restriction map of the kanamycin resistant ( $Km^R$ ) plasmid pIK86 which was employed in construction of expression vectors according to the invention.

Figure 6 depicts the restriction map of the plasmid pIK-EL, which contains the EL cspA promoter.

Figure 7 depicts the DNA sequence of the EL cspA promoter, which is comprised approximately of the nucleotides between the arrows labeled "EL". The sequence of the EL cspA promoter contained in pIK-EL is set forth in SEQ ID NO:3.

Figure 8 depicts the restriction map of the plasmid pIK-L, which contains the L cspA promoter.

Figure 9 depicts the DNA sequence of the L cspA promoter, which is comprised approximately of the nucleotides between the arrows labeled "L". The sequence of the L cspA promoter contained in pIK-L is set forth in SEQ ID NO:4.

-6-

Figure 10 depicts the restriction map of the plasmid pIK-M, which contains the M cspA promoter.

Figure 11 depicts the DNA sequence of the M cspA promoter, which is comprised approximately of the nucleotides between the arrows labeled "M". The sequence of the M cspA promoter contained in pIK-M is set forth in SEQ ID NO:5.

Figure 12 depicts the restriction map of the plasmid pIK-S, which contains the S cspA promoter.

Figure 13 depicts the DNA sequence of the S cspA promoter, which is comprised of the nucleotides between the arrows labeled "IS". The sequence of the S cspA promoter contained in pIK-S is set forth in SEQ ID NO:6.

Figure 14 depicts (A) the presence of the cspA promoter in the plasmid pIK86 and its insertion into phage  $\lambda$ B299 by means of a double crossover recombination event and (B) the resulting vector  $\lambda$ PcspA ( $\lambda$ PcspA).

Figure 15 depicts the temperature response of the pL-9G-50 promoter fused to a lacZ reporter gene and integrated in the bacterial chromosome in the presence (i.e.,  $hip^+$ , ●) and absence (i.e.,  $hip^-$ , ○) of the positive regulator of the pL promoter, host integration factor.

Figure 16 depicts the temperature response of the pL-9G-50 promoter fused to a lacZ reporter gene and integrated in the bacterial chromosome in the presence (i.e.,  $hip^+$ , ●) and absence (i.e.,  $hip^-$ , ○) of host integration factor. Cultures transferred from 37°C to about 15-16°C: (a)  $\beta$ -gal levels, (b) cell density. Cultures transferred from about 15-16°C to 37°C: (c)  $\beta$ -gal levels, (d) cell density.

Figure 17 depicts the expression of lacZ under the control of various cspA promoters at about 15-16°C: (□) endogenous cspA mRNA; (●) EL-lacZ mRNA; (■) M-lacZ mRNA; (▲) S-lacZ mRNA.

SUBSTITUTE SHEET (RULE 26)



-7-

Figure 18 depicts a partial restriction map of plasmid pHG309 (a derivative of plasmid pHG87) and pL-plac (which responds to the lac repressor and is enhanced by pL promoter elements).

Figure 19 depicts the expression of lacZ, in terms of enzyme activities and messenger RNA level, under the control of various cspA promoters, at 37 and 15°C.

#### Best Mode For Carrying Out The Invention

The invention relates to expression vectors which lead to the high level expression of subcloned genes in bacterial host cells at low temperatures (i.e., at temperatures less than about 20°C), and which allow the production of proteins in their native and active form.

The invention is based on the premise that the rate of protein folding will be only slightly affected by lowering the temperature to about 15-20°C, while the rate of transcription and protein synthesis, being biochemical reactions, will be greatly slowed down (e.g. 5- to 10-fold). Exploitation of these conditions, as in the context of the present invention, allows individual proteins sufficient time to refold in an independent way, yielding active proteins and preventing the formation of aggregates, without reducing the final yield of the desired protein.

Accordingly, the invention provides vectors which allow for the production of native and active eukaryotic protein in a bacterial host cell.

Fermentation in bacterial host cells containing such vectors is based on a two-stage process. At the first stage there is rapid bacterial growth at high temperatures of about 37-43°C during which only a very low-level of expression of a subcloned gene contained within the vector takes place. At the second stage there is an increase of gene expression of the subcloned gene

-8-

upon transfer to the low temperature. Following fermentation, pure, soluble and highly active proteins can be isolated. The increased production of protein that occurs upon transfer of the host cells to low temperature requires utilizing the specifically designed expression systems which are the subject of the present invention. These vectors allow for increased gene expression and production of protein or peptides at a temperature below about 20°C.

By utilizing a high temperature for bacterial growth, the cell carrying the desired gene will grow rapidly without expressing the desired peptide. Following a change to lower temperature in the fermentation system, the expression of the gene encoding the foreign protein will be initiated. Finely tuning the rate of synthesis of the desired protein at low temperature yields high levels of soluble and biologically active proteins. This expression system is of general use and can be used for proteins such as viral proteins, especially those useful for preparing vaccines against viruses, in particular against hepatitis viruses such as hepatitis A, insulin, cytokines such as interleukins such as IL 1-13, in particular IL-2 $\alpha$ , interferons, clotting factor genes such as Factors I-XIII, in particular VIII, hormones such as follicle stimulating hormones, any glucocerebrosidase such as  $\beta$ -glucocerebrosidase and other growth factors and, in principle, any desired protein or peptide.

The vectors of the present invention comprise a nucleic acid sequence which comprises a gene encoding a desired protein or peptide, as well as a promoter which is highly active at low temperature. These vectors, upon introduction to a bacterial host cell, enable the high level production of the desired protein or peptide at low temperatures. The protein or peptide is obtained in a

SUBSTITUTE SHEET (RULE 26)

native active form, and therefore no additional manipulation of the protein, such as protein refolding, is required.

Accordingly, the present invention provides an expression vector comprising a nucleic acid sequence which comprises a gene and a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20°C, the production of a recombinant peptide or protein encoded by the gene contained within the vector.

In the context of the present invention, a promoter is a DNA sequence that directs the binding of RNA polymerase and thereby promotes nascent mRNA synthesis. The DNA sequences of eukaryotic promoters differ from those of prokaryotic promoters which means that eukaryotic signals may not be recognized in prokaryotic systems, and vice versa. Accordingly, the promoters of the present invention allow transcription of a gene contained within the vector and, moreover, allow increased transcription at temperatures below about 20°C.

Generally the gene inserted into the vector will be foreign (i.e., a gene that is not normally expressed in the particular host in which the vector will be introduced), and, preferably, the gene will be of eukaryotic origin. The gene may be wholly or partially synthetic. The protein or peptide encoded by the gene may comprise a full length protein, a polypeptide, or a chimeric protein.

Also, the vectors of the present invention must be capable of replication in a bacterial host (i.e., either autonomously or as part of the host genome), and must be capable of directing the production of the peptide or protein in the bacterial host. Thus, the vectors preferably comprise appropriate control elements (e.g.,

-10-

promoters and ribosome binding sites) for commanding the production of the peptide or protein in the host.

In some cases, the gene contained within the vector and encoding the protein or peptide will contain the appropriate regulatory elements such that these elements need not be present on the vector. In other cases (such as when a eukaryotic protein is being produced in a prokaryotic host), it is preferred that the vectors of the present invention comprise these additional elements. It is preferred that all of the proper transcription and translation signal be correctly arranged on the vector, such that the foreign gene will be properly expressed within the host, and protein will be translated, when the temperature is decreased to below at 20°C.

Accordingly, preferably the expression vectors of the present invention further comprise an initiation codon (such as an ATG codon) positioned so as to allow translation of the peptide or protein to initiate from the initiation codon. Even more preferable is that the initiation codon be positioned between said promoter and said gene.

Also, preferably the expression vectors of the present invention further comprise a ribosome binding site positioned so as to control translation of said peptide or protein, preferably positioned between the promoter and the translation initiation codon.

The presence of these additional control elements on the vectors may be necessitated by the fact that translation in prokaryotes, just like transcription, also does not proceed well in response to eukaryotic signals. For instance, initiation of translation in prokaryotes requires the presence of an initiation codon, such as the ATG codon. If the foreign DNA does not comprise such a codon, one or more such codons can be provided in the vectors of the present invention. Preferably the

**SUBSTITUTE SHEET (RULE 26)**

-11-

initiation codon will be placed upstream from the sequences through which translation is to initiate, and downstream of the promoters of the present invention which impart increased transcription at low temperatures upon subcloned fragments placed under their control.

Similarly, the vectors of the present invention may also comprise a ribosome binding site (i.e., a "Shine-Dalgarno sequence"; Shine et al., Nature (1975) 254:34). It is known that efficient translation in prokaryotes is dependent on such a sequence, which exhibits complementarity to the 3' end of the 16S ribosomal RNA (rRNA), and likely promotes binding of mRNA to ribosomes by duplexing with the rRNA, thus allowing the correct positioning of the ribosome on the mRNA. Accordingly, it is preferable that the ribosome binding site be contained within the vectors of the present invention upstream of the translation initiation codon and downstream of the promoters which impart increased transcription at low temperatures upon subcloned fragments.

Preferably, the vectors of the present invention further comprise additional operably-bound DNA sequences which contain other control elements. For instance repressor sites involved in the turning off of gene expression and enhancers involved in the augmentation of gene expression are contemplated in the context of the present invention.

The vectors of the present invention comprise a nucleic acid sequence preferably comprising DNA, which may be single or double-stranded. The vectors may exist as plasmids, cosmids (i.e., plasmids comprised of a cos site) or bacteriophages. In preferred embodiments of the present invention, the vector comprises a plasmid, or a bacteriophage, or may comprise a plasmid:bacteriophage cointegrate which may further be inserted into the bacterial chromosome.

**SUBSTITUTE SHEET (RULE 26)**

-12-

Preferred vectors of the present invention wherein the vector comprises a bacteriophage are:  $\lambda$ PcspA ( $\lambda$ A01131 deposited as ATCC No. 75718) and  $\lambda$ A01107 (deposited as ATCC No. 75717). Other preferred vectors include but are not limited to pHG87 and pHG91.

While prokaryotic species such as the bacterium *E. coli* stop growing at about 10°C, the vectors of the present invention allow production at a temperature of less than about 20°C (i.e., at about 15-16°C) of a high level of a peptide or protein encoded by a gene contained within the vector, for example, of the reporter gene lacZ.

The low temperature provides a way to regulate the level of gene expression, allowing the skilled artisan to find a temperature at which the expression rate will be reduced, and providing the maximal time needed for proper protein folding, thus preventing protein aggregation. In other words, as the rate of cell growth is slowed down at lower temperature, the relative time allowed for refolding of individual protein molecules will be increased.

The expression systems described herein are based on two different sets of promoters and regulatory elements. In one embodiment, the expression vectors according to the invention comprise the cold-sensitive pL promoter of phage  $\lambda$ . Descriptions in the literature of the use of the pL promoter of phage  $\lambda$  and its thermosensitive cI repressor mutant have been extensive. Typically, cells are first grown at 30°C until a high cell mass is reached. At that stage, the cells are transferred to 42°C and repression of the pL promoter is lifted, leading to the enhanced expression of a subcloned gene placed under the control of the pL promoter (see, e.g., Giladi et al., J. Mol. Biol. (1992) 227:985-990; Giladi et al., J. Mol. Biol. (1992) 224:937-948; Ptashne, Genetic

SUBSTITUTE SHEET (RULE 26)

Switch: Phage Lambda and Higher Organisms (Cell Press & Blackwell Scientific Publications, Cambridge, MA (1992)).

However, the present invention comprises a pL mutant promoter that is most active at a low temperature (i.e., a temperature less than about 20°C). In addition it was discovered in the context of the present invention that the wild-type and improved mutants of the pL promoter (e.g., pL-9G-50) are also highly active at temperatures less than about 20°C.

A number of pL derivatives were constructed using conventional recombinant DNA techniques and tested for promoter response to low temperature as described in Example 2 below. A 3 base pair mutant at the region from -4 to +4 of the transcription start site (which altered the sequence from GCACATCA to GGACAAGA) diminished the cold-response. Other nucleotide substitutions at other sites within this region, in particular the sites appearing in bold text, should provide similar results. A similar reduction in the cold-response was obtained when sequence at the -10 region of the pL promoter was changed from GATACT to TATAAT. Other nucleotide substitutions at other sites within this region, in particular the sites appearing in bold text, should provide similar results. A -9G mutation (in which the sequence GATACT was changed to GATGCT) resulted in a significant response upon transfer to low temperature. Other nucleotide substitutions at other sites within this region, in particular the site appearing in bold text, should provide similar results.

PHG309, a pL promoter derivative in which an internal deletion, spanning nucleotides -40 to -70, was introduced, retains the response to low temperature but does not require IHF for full activity. To obtain the -40 to -78 deletion, two successive PCR reactions were used. In the first reaction, a pL fragment extending

-14-

from -130 to -79 and carrying at the 3' end an additional 12 base pairs from -39 to -28, was engineered using primers #1815 (5'-TCAGAATTCTCACCTACC-3') and #2319 (5'-TATGTCAACACCTTTTTTATATG-3'). In the second reaction, primers #2011 (5'-AAGGATCCAATGCTTCGTTT-3') and the product of the first PCR reaction were used. This promoter was found, when present on a multicopy plasmid, to be about 7 to 15 fold more active than the -9G-50 mutant, depending on growth conditions (as assayed by  $\beta$ -galactosidase activity). It is expected that other mutants which contain lesser deletions in this same area (so long as the open reading frame is maintained) will similarly retain low temperature responsiveness and may also may not require IHF for full activity.

The pL-Plac chimeric promoter was generated in a similar way, using primer #1815 and a chimeric primer #4402 (5'-ACGAGCCGGAAGCATAAAGTGTAATGTTTTTATATGAA-3') on a pL template in the first PCR reaction. In the second reaction, the product of the first reaction was used as the upstream primer. The universal M13 primer was employed and the Plac promoter served as template. In this fusion product, expression is regulated by the lacI repressor and can be induced by IPTG. The region from -130 to -79 of pL was fused to Plac (from -36 to +84). The response of this promoter to low temperature was not tested.

In another embodiment, the expression vectors of the invention comprise the cspA promoter. This promoter is highly responsive to low temperatures, and, in its native position in the bacterial chromosome, directs the synthesis of over 13% of the bacterial proteins synthesized (Tanabe et al., J. Bacteriol. (1992) 174:3867; Goldstein, Proc. Nat. Acad. Sci. (1990) 87:283). The cspA gene is the major cold shock gene that has been described in bacteria (Goldstein et al., Proc.

SUBSTITUTE SHEET (RULE 26)



-15-

Natl. Acad. Sci. (1990) 87:283; Jones et al., J. Bacteriol. (1992) 174:3903; Tanabe et al., J. Bacteriol. (1992) 174:3867).

The promoter region of the cspA gene has been dissected, allowing the identification of a number of regions involved in the enhancement of transcription. The strength of this promoter allows certain clones to be maintained only at high temperatures. The influence of the cspA promoter on lacZ expression in the context of the present invention was confirmed as illustrated in the Examples.

A spontaneous mutation in the -35 region (a T:A to C:G mutation at -36) greatly increases the partition of expression between high and low temperature (and see Figure 19). It is expected that any nucleotide substitution at this position would provide similar results. It is further expected that other mutations  $\pm 5$  of the -35 site will provide similar results.

Accordingly, preferred vectors of the present invention comprise a pL promoter or a PcspA promoter. The pL promoter and PcspA promoter may further comprise a mutation or mutations. In the context of the present invention, a mutation results in an alteration of the DNA sequence, and may consist of an addition, deletion or substitution in the base sequence. Some mutations of the PcspA promoter according to the present invention are contained within, for example, pIK-L and pIK-M. Similarly, a PcspA mutation according to the present invention is contained within pL-9G-50.

Other preferred vectors of the present invention comprise vectors in which the promoter comprises the sequence of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; or SEQ ID NO:6.

Other preferred vectors include:  $\lambda$ A01107 contained within the cell line deposited with the ATCC and assigned

**SUBSTITUTE SHEET (RULE 26)**

-16-

No. 75717;  $\lambda$ PcspA contained within the cell line deposited with the ATCC and assigned No. 75718; pIK-M contained within the cell line deposited with the ATCC and assigned No. 75719; pIK-EL contained within the cell line deposited with the ATCC and assigned No. 76720; and the plasmids pIK-L and pIK-P.

The present invention further relates to a host-vector system for the production of a desired protein in native active form which comprises an expression vector according to the present invention in a suitable bacterial, and preferably *E. coli*, host cell.

Also, the expression of the pL promoter is positively regulated by HIF, which is a natural component of *E. coli* host cells. Accordingly, HIF<sup>+</sup> *E. coli* strains, which contain the known host integration factor, HIF, are preferred for use with the vectors of the present invention comprising the pL promoter.

Generally, even more preferred *E. coli* strains are those which contain mutations that will increase the level of protein production and/or stability, or will correct the folding of the desired gene products. Such strains are, for example, mutants defective in the lon or hfl genes, which may improve stability by reducing proteolysis. Additionally, preferred strains may comprise mutations in recA or other recombination/repair genes, such mutations which are known to be involved in recombination, including deletions, of eukaryotic DNA contained within bacterial hosts.

Accordingly, the present invention provides a bacterium containing the vector in which the promoter comprises the sequence of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; or SEQ ID NO:6.

Similarly, the present invention comprises a nucleic acid comprising a vector in which the promoter comprises

**SUBSTITUTE SHEET (RULE 26)**

-17-

the sequence of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; or SEQ ID NO:6.

Other preferred host-vector systems for the production of  $\beta$ -gal in native active form comprise the  $\lambda$ PcspA or  $\lambda$ A01107 expression vectors in a suitable *E. coli* host cell, particularly strain A7506.

In a preferred host-vector system, the gene encoding the desired protein or peptide is integrated into a suitable *E. coli* host cell chromosome through use of the phage  $\lambda$  expression vectors. Integration into the chromosome results in a single copy of the gene fusion which is extremely stable, and which allows for performing the fermentation procedure without the use of antibiotics.

Genes can be stably introduced into the bacterial chromosome using the method of the present invention. Under these conditions, the pL promoter can be maintained in the cell in the absence of the cI repressor. A low level of expression is found when the cells are grown at elevated temperatures, and a high level of expression is found when the cells are transferred to a low temperature.

In order to further improve the system so as to allow the use of plasmids and further increase protein production, a mutant repressor that is active at high temperature but not at low temperature can be incorporated within the *E. coli* chromosome or subcloned into a plasmid vector. When supplied with this mutant repressor, cell cultures could be grown at 37°C before being transferred to lower temperature to allow for the expression of the cloned gene. It is possible to use the system as plasmids. It is possible that to acquire greater protein stability, the host has to be grown at 42°C before lowering the temperature. It is probable that specific growth conditions will have to be

SUBSTITUTE SHEET (RULE 26)

-18-

developed, depending on the gene to be expressed. Thus, homologous recombination is not essential.

In contrast to the pL promoter, positive or negative regulators of the cspA promoter have not been identified. Using the appropriate promoter constructs according to the present invention, it is possible to directly manipulate promoter activity. Cells carrying proper fusions will be grown at 37°C or higher temperatures, and fusions will be induced by a change in the culture temperature (i.e., lowering the temperature below about 20°C).

The present invention further provides a method of producing a desired protein encoded by a subcloned gene contained within an expression vector which comprises introducing the expression vector into a suitable host cell, preferably a bacterial host cell, maintaining the cell in culture, and isolating the protein produced.

Cell expansion is facilitated by growing cells between 15 to 45°C. Preferably the cell is maintained in culture at a temperature of about 37°C for a suitable length of time to allow an increase in cell growth, and is then maintained in culture at a temperature below about 20°C (between 10 and 20°C) for a suitable length of time to allow production of protein. Cells are grown at elevated temperature followed by transfer to low temperature, while sampling at four hour intervals (up to 72 hours) in order to determine the highest activity. Samples are also evaluated by protein gel electrophoresis.

Isolation of protein can be by any technique known in the art for the purification of proteins, such as chromatography, centrifugation, differential solubility, isoelectric focusing, etc. However, preferably the foreign protein will be obtained from the bacterial host cell by suitable means whereby the protein is recovered

**SUBSTITUTE SHEET (RULE 26)**

-19-

in native active form. Cells are harvested and lysed using standard procedures. It is possible that specific buffer conditions will be required to prevent *in vitro* aggregation of protein.

Standard culture media, rich or minimal, can be used in the context of the present invention. As mentioned above, with suitable vectors, addition of antibiotics to the culture media can be avoided, which may be of particular advantage for production of certain proteins.

The following examples further illustrate the present invention but, of course, should not be considered as in any way limiting its scope.

#### EXAMPLE 1: Materials and Methods

##### Employed in Experiments

##### Bacterial strains, phages and plasmids

In the present experiments, standard molecular and genetic techniques such as generation of strains, phages and plasmids, gel electrophoresis, DNA manipulations including cloning and sequencing, primer extension assays, etc., were performed such as are known to those skilled in the art and are described in detail in standard laboratory manuals (e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor, NY, 1992); Ausubel et al., Current Protocols in Molecular Biology, (1987); Miller, A Short Course in Bacterial Genetics, (Cold Spring Harbor, NY, 1992)). Restriction enzymes and other enzymes used for molecular manipulations were purchased from commercial sources, and used according to recommendations. Strains were cultured, and phages were maintained, propagated and titered using standard reagents, media and techniques (Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor, NY, 1992); Miller, Experiments in Molecular Genetics (Cold Spring Harbor

-20-

Laboratory Press, Cold Spring Harbor, NY, 1972)). Preferably, Luria-Bertani (LB) Medium containing Bacto tryptone (10 g/l), Bacto yeast extract (5 g/l) and NaCl (10 g/l) was employed for growth of cells.

*E. coli* strain A7506 is a derivative of CSH50 (ara  $\Delta$ (lac-pro) strA thi; described in Miller, Experiments in Molecular Genetics (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1972)) which carries the  $\lambda$ A01107 prophage. Strains A7507, a hip3::cat derivative of A7506, and A7533, a himA82:Tn10 derivative of A7507, were generated by Plvir transduction.

Strain A6826 is a CSH50 derivative. Strain CSH50 was found to grow slowly on minimal medium plates containing the supplements vitamin B<sub>1</sub> and proline. A fast growing colony of CSH50 was isolated, purified and designated A6826. Strain 7833 is a  $\lambda$ cspA EL-lacZ derivative of A6826 and strain 7832 is a  $\lambda$ cspA S-lacZ derivative of A6826.

The DNA sequence of the pL promoter region including the nucleotides flanking the Eco RI and Bam HI sites is shown in Figure 1, and is set forth in SEQ ID NO:1. Plasmid pHG87 contains the fragment comprising the wild-type pL promoter, as shown in Figure 2.

The restriction map of plasmid pHG91 is shown in Figure 3. Plasmid pHG91 contains the mutant pL promoter pL-9G-50. The sequence of this mutant promoter is characterized by an (A:T) to (G:C) mutation at basepair 220, and a GGCC sequence substituting AATT at basepairs 177-180, and is set forth in SEQ ID NO:2.

Plasmid pHG91 was obtained by fusing the pL-9G-50 promoter to the lacZ reporter gene present in plasmid pHG86 (Giladi et al., J. Mol. Biol. (1992) 224:937-948). A kanamycin resistance gene ( $Km^R$ ) was then inserted in the Pst I restriction site located within the bla gene of pHG91 to generate plasmid pHG91K. When in full length

SUBSTITUTE SHEET (RULE 26)

-21-

form, the lacZ gene encodes  $\beta$ -galactosidase ( $\beta$ -gal) and the bla gene (sometimes designated amp) encodes a  $\beta$ -lactamase and confers host cell resistance to ampicillin.

Phage  $\lambda$ A01107 is the product of recombination between phage  $\lambda$ B299 and plasmid pHG91K, as set forth in Figure 4. Phage  $\lambda$ B299 (obtained from R. Weisenberg, Section on Microbial Genetics, Laboratory of Molecular Genetics, National Institutes of Health) carries the supF gene flanked by the truncated lacZ and bla genes. Recombination between phage  $\lambda$ B299 and plasmid pHG91K results in the replacement of the supF gene by the pL-lacZ fusion from pHG91K in phage  $\lambda$ A01107.

Plasmids phip<sup>+</sup>, pR87G and pA90D are pEMBL18 derivatives, carrying the wild-type hip gene and its mutant alleles  $\beta$ R87G and  $\beta$ A90D (Menegeritsky et al., J. Mol. Biol. (1993) 231:646-657).

The cspA promoter fragment (309 bp in length from positions -214 to +95; Goldstein et al., PNAS (1990) 87:283-287) was cloned using the polymerase chain reaction (PCR; PCR Protocols, A Guide to Methods and Applications, Innis et al., eds., Academic Press, Inc. (1990)), and was inserted into the plasmid pHG86 upstream of the reporter lacZ gene. Plasmid pIK86 (shown in Figure 5) was constructed from pHG86 by inserting Km<sup>R</sup> within the bla gene. A set of constructs containing different sized portions of the cspA promoter region was then prepared from pIK86. The different size fragments carrying the pcspA promoter region were each generated by PCR using a lambda phage carrying the cspA chromosomal region. Two primers were also employed: a primer homologous to the 5' region and carrying an Eco RI restriction site; and a primer homologous to the 3' region and carrying a Bam HI restriction site. The restriction maps of the cspA promoter constructs generated were determined.

-22-

Of the cspA promoter region-containing plasmids, pIK-EL contains the largest upstream cspA promoter region, as indicated in Figure 6. The sequence of the cspA fragment subcloned in the pIK-EL vector is given in Figure 7 and SEQ ID NO:3. A smaller cspA promoter fragment was subcloned into pIK-L, as indicated in Figure 8. The sequence of the cspA fragment subcloned in the pIK-L vector is given in Figure 9 and SEQ ID NO:4. Similarly, pIK-M contains a still smaller cspA fragment, as indicated in Figure 10. The sequence of the cspA fragment subcloned in the pIK-M vector is given in Figure 11 and SEQ ID NO:5. The smallest cspA promoter fragment was subcloned into pIK-S, as indicated in Figure 12. The sequence of the cspA fragment subcloned in the pIK-S vector is given in Figure 13 and SEQ ID NO:6.

Since cspA is a strong promoter, in order to reduce the level of expression being driven by the cspA promoter at high temperatures, these constructs were subsequently transferred to phage  $\lambda$  by homologous recombination, as set forth in Figure 14. The phage was then integrated into an *E. coli* chromosome. All crosses between plasmids and  $\lambda$ B299 were carried out in strain A6826.

#### Preparation of DNA Fragments

DNA fragments used for the primer extension assay were obtained by PCR using Taq Polymerase (Promega Corp. Madison, WI). To obtain the 275-bp pL DNA fragment, primer 1921 5'-AAGAATTCGGGTTTTCTTT-3' (pL positions -228 to -217 as set forth in SEQ ID NO: 7), primer 1526 5'-AAGAGCGTCACCTTC-3' (pL positions +40 to +26 as set forth in SEQ ID NO: 8) and plasmid pHG244 DNA as a template were employed (Giladi et al., J. Mol. Biol., (1992) 224: 937-948). All DNA fragments were end-labeled with ( $\gamma^{32}$ P)ATP (Amersham Corp., Arlington Heights, IL) and purified on a 5% polyacrylamide gel.



### Enzymatic assays

Assays of  $\beta$ -gal specific activity were carried out according to Miller (Miller, Experiments in Molecular Genetics (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1972)).

### EXAMPLE 2: Temperature Response of the pL promoter

To test the influence of temperature on gene expression driven by the attenuated pL-9G-50 promoter, this promoter was fused to the lacZ gene and inserted into the *E. coli* chromosome at the att site using phage  $\lambda$ , and generating strain A7506.

Cultures of strain A7506 were grown in LB medium at various temperatures to saturation, and were assayed for  $\beta$ -gal activity. As can be seen from Figure 15, the levels of  $\beta$ -gal present in the cell were quite high at low temperatures (i.e., less than about 20°C) and declined precipitously with increases in temperature. This temperature effect was not observed when cultures of strain A7507 were employed. Strain A7507 is a *hip* derivative of strain A7506 which does not produce host integration factor, a positive regulator of the pL promoter. In strain A7507, levels of  $\beta$ -gal were low at all temperatures.

These results confirm that gene expression driven by the pL-9G-50 promoter is induced by low temperatures.

### EXAMPLE 3: Temperature Shift Experiments

To study the response of the attenuated pL-9G-50 promoter to temperature changes, temperature shift experiments of the lacZ fusion of this promoter present in the chromosome of strain A7506 were performed.

For these experiments, cultures of strain A7506 (*hip*<sup>+</sup>) and A7507 (*hip*<sup>-</sup>) were grown exponentially at 37°C

-24-

or about 15-16°C, and were then transferred to the alternate temperature (i.e., a culture grown at 37°C was transferred to about 15-16°C, and a culture grown at about 15-16°C was transferred to 37°C). Levels of  $\beta$ -gal as well as cell density were determined at different times after the temperature shift.

When exponentially growing A7506 cells were transferred from 37°C to 15-16°C, a dramatic increase in  $\beta$ -gal levels was observed as indicated in Figure 16a. This increase occurred despite the long lag in cell growth due to the cold shock, as demonstrated in Figure 16b, and was dependent on the presence of the wild-type hip gene, as it was not observed for the A7507 cells under the same conditions.

In contrast, when exponentially growing A7506 cells were transferred from 15-16°C to 37°C, a rapid cessation in  $\beta$ -gal specific activity was observed, as indicated in Figure 16c. This decrease in  $\beta$ -gal specific activity correlates with the dilution of the existing enzyme by cell division (as indicated in Figure 16d), possibly because transcription from pL was turned off rapidly after transfer to the higher temperature.

These results confirm that the attenuated pL-9G-50 promoter is able to drive a high level of gene expression upon transfer from 37°C to about 15-16°C.

#### EXAMPLE 4: Effect of Temperature on Promoter Activity

The pL-9G-50 and P<sub>cspA</sub> promoters were each fused to the lacZ gene in an operon fusion, transferred to phage  $\lambda$ B299 by homologous recombination, and inserted at the att site of the bacterial chromosome as described above. Strain N99 was employed as a control to measure p<sub>lac</sub> activity from its authentic operon (Ueshima et al., Mol. Gen. Genet. (1989) 215:185-189). These experiments were

**SUBSTITUTE SHEET (RULE 26)**

-25-

done to determine whether the temperature response of the pL promoter is unique to that promoter.

For these experiments, cell cultures were grown to saturation in LB medium at 37°C or about 15-16°C, and were then assayed for  $\beta$ -gal activity. Results are as summarized in Table 1.

TABLE 1

Promoter	$\beta$ -gal units	
	15-16°C	37°C
pL-9G-50	3860	260
<u>plac</u>	5950	7320
<u>PcspA</u>	1430	85

These results confirm that the PcspA promoters as well as the pL-9G-50 promoter are able to drive a high level of gene expression at low temperatures (i.e., less than about 20°C). Expression driven by these promoters at about 15-16°C approaches that driven by the strong promoter plac. In contrast, expression of plac is reduced about 10-20% at 15-16°C as compared with at 37°C.

These results suggest that the higher enzyme levels observed for the pL promoter at low temperatures are due to increased pL transcription rather than to increased stability of the enzyme, or to more efficient protein translation. Contrary to the plac promoter, the cspA promoter was 20-fold more active at 15-16°C than at 37°C. It is noteworthy that the pL promoter showed the same temperature activation profile as PcspA. This temperature response is an intrinsic property of the pL promoter, and individual promoters appear to have an inherent response to temperature which is embedded within the promoter DNA sequence. The extent of response of the

-26-

pL promoter to low temperatures, i.e., 14-fold higher at 15-16°C than at 37°C, is similar to that of the cspA promoter, yet these two promoters do not share DNA sequence similarities that indicate why they are more active at low temperature.

Thus, the pL-9G-50 and PcspA promoters minimally drive gene expression at temperatures at which bacterial cell growth and replication is optimized (i.e., at about 37°C). This validates that the promoters can be employed to obtain maximal gene expression at temperatures at which bacterial cell growth and replication are minimized (i.e., less than about 20°C).

**EXAMPLE 5: Single Copy Chromosomal Fusion by  
Recombination between Phage  $\lambda$  and Plasmid**

Similar experiments as in Example 4 done with the various pIK-cspA constructs confirm that these also are strong promoters, and that in fact, the EL and L constructs are difficult to maintain in host cells, possibly due to lethality as a consequence of a high level of gene expression. In order to reduce the level of expression driven by the cspA constructs at high temperatures, the constructs were transferred to phage  $\lambda$ B299 by homologous recombination (as indicated in Figure 14A-B). The resultant phages were then integrated into the bacterial chromosome, resulting in a single copy per cell.

As can be seen from Table 2, gene expression driven by the various cspA promoters as reflected in  $\beta$ -gal levels is temperature-regulated and is rather high in the resultant strains even though these strains contain only a single copy of the lacZ gene fusions.

-27-

TABLE 2

Single Copy	B-gal Units	
	about 20°C	37°C
$\lambda$ IK-EL	20000	1000
$\lambda$ IK-M	24000	2000
$\lambda$ IK-S	9000	900
$\lambda$ IK-P	11170	2440

The single copy system is extremely stable and allows for performing the fermentation procedure without the use of antibiotics. Similar results to those as shown above for the pL promoter demonstrate that the pL wild-type promoter, which cannot be maintained in the absence of repressor, can direct the expression of lacZ in a single copy.

These results confirm that the various cspA promoters (as well as the pL-9G-50 promoter) can effectively drive gene expression at low temperatures resulting in a high level of translated protein when present as only a single copy integrated into the bacterial chromosome.

Example 6: Influence of PcspA promoter on lacZ expression at low temperatures

To test the PcspA promoter influence on lacZ expression, cells carrying the EL-lacZ fusion (i.e., strain A7833), the M-lacZ fusion (i.e., strain A7831) and the S-lacZ fusion (i.e., strain A7832) on phage  $\lambda$  as a single copy in the bacterial chromosome, were examined.

For these experiments, cultures were grown in LB at 37°C, and were transferred to about 15-16°C at time 0. Samples were taken at 1, 2, 4 and 6 hours intervals, and RNA was isolated and assayed by primer extension using

-28-

labeled primers and reverse transcriptase. Radioactivity of the band corresponding to the transcription start site was determined.

As can be seen in Figure 17, the endogenous cspA mRNA (i.e., □) is present at high levels only one hour after transfer to the low temperature. In contrast, EL-lacZ (i.e., ●) and M-lacZ (i.e., ■) mRNAs are maintained at high levels for longer time periods. Only basal levels of S-lacZ (i.e., ▲) mRNA were observed at all temperatures.

These results confirm that the EL and M promoters may be used to drive gene expression at low temperatures, and that the increased expression from these promoters is reflected in an increased level of transcribed mRNA.

All of the references cited herein are hereby incorporated in their entireties by reference.

While this invention has been described with an emphasis upon a preferred embodiment, it will be obvious to those of ordinary skill in the art that variations in the preferred methods may be used, including variations due to improvements in the art, and that it is intended that the invention be practiced otherwise than as specifically described herein, to encompass these variations. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

-29-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Oppenheim, Amos B.  
Giladi, Hilla  
Goldenberg, Daniel  
Kobi, Simi  
Azar, Idit
  - (ii) TITLE OF INVENTION: VECTORS AND TRANSFORMED HOST CELLS  
FOR RECOMBINANT PROTEIN PRODUCTION AT REDUCED  
TEMPERATURES
  - (iii) NUMBER OF SEQUENCES: 8
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Leydig, Voit & Mayer, Ltd.
    - (B) STREET: 700 Thirteenth Street, N.W., Suite 300
    - (C) CITY: Washington
    - (D) STATE: D.C.
    - (E) COUNTRY: US
    - (F) ZIP: 20005
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Floppy-disk
    - (B) COMPUTER: IBM PC compatible
    - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
    - (D) SOFTWARE: PatentIn Release #1.0, version #1.25
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER: US
    - (B) FILING DATE: July 21, 1994
    - (C) CLASSIFICATION:
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Rose, Herbert C.
    - (B) REGISTRATION NUMBER: 28946
    - (C) REFERENCE/DOCKET NUMBER: 60170
  - (ix) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: (202) 737-6770
    - (B) TELEFAX: (202) 737-6776
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 343 base pairs

SUBSTITUTE SHEET (RULE 26)

-30-

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

CGGGTTTTCT TTGCCTCACG ATCGCCCCCA AAACACATAA ATAAATAGAT ACAACTCACT 60
AAACATAGCA ATTCAGATCT CCCCTGCAAA AAATAAATTC ATATAAAAAA CATACAGATA 120
ATCTCTGGCG GTGTTGACAT AAATACCACT GGCGGTGATA CACTGACCAC CATGAAGGTG 180
ACGCTCTTAA AAATTAAGCC CCAATTGTAT TTATTGAAAA CTCACCTACC AAACAATGCC 240
ACCATCTGCG GTGATAAATT CTGAGCACAT CAGCAGGACG CTGAAGAAGG GCAGCATTCA 300
AAGCAGAAGG CTTTGGGGTG TGTGATACGA AACGAAGCAT TGG 343

```

(3) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 343 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

CGGGTTTTCT TTGCCTCACG ATCGCCCCCA AAACACATAA CCAATTGTAT TTATTGAAAA 60
ATAAATAGAT ACAACTCACT AAACATAGCA ATTCAGATCT CTCACCTACC AAACAATGCC 120
CCCCTGCAAA AAATAAATTC ATATAAAAAA CATACAGAT ACCATCTGCG GTGATAGGCC 180
ATCTCTGGCG GTGTTGACAT AAATACCACT GGCGGTGATG CTGAGCACAT CAGCAGGACG 240
CACTGACCAC CATGAAGGTG ACGCTCTTAA AAATTAAGCC CTGAAGAAGG GCAGCATTCA 300
AAGCAGAAGG CTTTGGGGTG TGTGATACGA AACGAAGCAT TGG 343

```

(4) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 280 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY:

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

CAGACGCGTG AAGCCTTCAA GTGCCGAAC AAAATTGATG CGTTTGATTG AAGCCAACCC 60
GGCATTAAAGT AAGCAGTTGA TGAATAGAC TTTATCCAC TTTATTGCTG TTTACGGTCC 120
TGATGACAGG ACCGTTTTCC AACCGATTAA TCATAAATAT GAAAAATAAT TGTTCATCA 180
CCCGCCAATG CGTGGCTTAA TGCACATCAA CGGTTTGACG TACAGACCAT TAAAGCAGTG 240
TAGTAAGGCA AGTCCCTTCA AGAGTTATCG TTGATACCCC TCGTAGTGCA 290

```

(5) INFORMATION FOR SEQ ID NO:4:

SUBSTITUTE SHEET (RULE 26)



-31-

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 185 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY:

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

TGCTGTTTAC GGTCTGATG ACAGGACCGT TTTCCAACCG ATTAATCATA AATATGAAAA 60
ATAATTGTTG CATCACCCGC CAATGCGTGG CTTAATGCAC ATCAACGGTT TGACGTACAG 120
ACCATTAAAG CAGTGTAGTA AGGCAAGTCC CTTCAAGAGT TATCGTTGAT ACCCCTCGTA 180
GTGCA                                           185

```

## (6) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY:

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

TCATAAATAT GAAAATAAT TGTTGCATCA CCGCCAATG CGTGGCTTAA TGCACATCAA 60
CGGTTTGACG TACAGACCAT TAAAGCAGTG TAGTAAGGCA AGTCCCTTCA AGAGTTATCG 120
TTGATACCCC TCGTAGTGCA                               140

```

## (7) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 121 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY:

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

TTGTTGCATC ACCCGCCAAT GCGTGGCTTA ATGCACATCA ACGGTTTGAC GTACAGACCA 60
TTAAAGCAGT GTAGTAAGGC AAGTCCCTTC AAGAGTTATC GTTGATACCC CTCGTAGTGC 120
A                                           121

```

## (8) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

-32-

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGAATTCGG GTTTTCTTT

19

(9) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAGAGCGTCA CCTTC

15

SUBSTITUTE SHEET (RULE 26)

-33-

Claims

1. An expression vector comprising a nucleic acid sequence which comprises a gene and a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20°C, the production of a peptide or protein encoded by said gene.

2. The vector of claim 1 wherein said nucleic acid sequence further comprises an initiation codon positioned between said promoter and said gene so as to allow translation of said peptide or protein to initiate at said initiation codon.

3. The vector of claim 2 wherein said nucleic acid sequence further comprises a ribosome binding site positioned so as to control translation of said peptide or protein.

4. The vector of claim 3 wherein said ribosome binding site is positioned between said promoter and said initiation codon.

5. The vector of claim 4 wherein said nucleic acid sequence further comprises additional operably-bound DNA sequences which contain other control elements.

6. The vector of claim 1 wherein said vector is circular and comprises double-stranded DNA.

7. The vector of claim 1 wherein said vector comprises a bacteriophage.

**SUBSTITUTE SHEET (RULE 26)**

-34-

8. The vector of claim 1 wherein said promoter is selected from the group consisting of the pL and PcspA promoters.

9. The vector of claim 8 wherein said promoter is a pL promoter.

10. The vector of claim 8 wherein said promoter is a PcspA promoter.

11. The vector of claim 9 wherein said pL promoter comprises a mutation or mutations.

12. The vector of claim 1 wherein said promoter comprises the sequence of SEQ ID NO:1.

13. The vector of claim 1 wherein said promoter comprises the sequence of SEQ ID NO:2.

14. The vector of claim 1 wherein said promoter comprises the sequence of SEQ ID NO:3.

15. The vector of claim 1 wherein said promoter comprises the sequence of SEQ ID NO:4.

16. The vector of claim 1 wherein said promoter comprises the sequence of SEQ ID NO:5.

17. The vector of claim 1 wherein said promoter comprises the sequence of SEQ ID NO:6.

18. The vector of claim 1 which comprises  $\lambda$ A01107 contained within the cell line of ATCC No. 75717.

**SUBSTITUTE SHEET (RULE 26)**

-35-

19. The vector of claim 1 which comprises  $\lambda$ PcspA contained within the cell line of ATCC No. 75718.

20. The vector of claim 1 which comprises plasmid pIK-M contained within the cell line of ATCC No. 75719.

21. The vector of claim 1 which comprises plasmid pIK-EL contained within the cell line of ATCC No. 76720.

22. A host cell containing the vector of claim 12.

23. A host cell containing the vector of claim 13.

24. A host cell containing the vector of claim 14.

25. A host cell containing the vector of claim 15.

26. A host cell containing the vector of claim 16.

27. A host cell containing the vector of claim 17.

28. A nucleic acid comprising the vector of claim 12.

29. A nucleic acid comprising the vector of claim 13.

30. A nucleic acid comprising the vector of claim 14.

31. A nucleic acid comprising the vector of claim 15.

32. A nucleic acid comprising the vector of claim 16.

**SUBSTITUTE SHEET (RULE 26)**

-36-

33. A nucleic acid comprising the vector of claim 17.

34. A method of producing a protein, which method comprises introducing the expression vector of claim 1 into a suitable host cell, maintaining said cell in culture so as to produce a protein, and isolating said protein.

35. The method of claim 34 wherein said cell is maintained in culture at a temperature of about 37°C for a suitable length of time to allow an increase in cell growth, and is then maintained in culture at a temperature below about 20°C for a suitable length of time to allow production of said protein.

36. The vector of claim 8 wherein said promoter is a pL promoter in which the -4 to +4 region shown in Figure 1 has been mutated from GCACATCA to GGACAAGA.

37. The vector of claim 8 wherein said promoter is a pL promoter in which the -10 region shown in Figure 1 has been mutated from CATACT to TATAAT.

38. The vector of claim 8 wherein said promoter is a pL promoter in which the -40 to -78 region shown in Figure 1 has been deleted.

39. The vector of claim 8 wherein said promoter is a pL promoter in which the -9 region shown in Figure 1 has been mutated from CATACT to GATGCT.

**SUBSTITUTE SHEET (RULE 26)**

1 / 1 8

# pL DNA

ECORI | L2  
 GGCCTCAGCGCGGGTTTCTTGGCCTCAGATCGCCCCCAAAACACATAACCAATTGTATTATTGAAAAA  
 CCGGAGTCGGCGGCCAAAGAAACGGAGTGCTAGCGGGGTTTGTGTATTGGTTAACATAAATACTTTT

TAAATAGATACAACTCACTAAACATAGCAATTCAGATCTCTCACCTACCAACAATGCCCCCTGCAAAAA  
 ATTTATCTATGTTGAGTGATTGTATCGTTAAGTCTAGAGAGTGGATGGTTTGTACGGGGGACGTTTTT

## BglII

L1

TAAATTCATATAAAAAACATACAGATGACCATCTGCGGTGATGAAATGATCTCTGCGGTGACATATAATA  
 (-50) GGCC ||| -10 -35  
 (sex1) T  
 pL2 → -35

RECTIFIED SHEET (RULE 91)

FIG. 1A

ATTAAAGTATATTTTGTATGCTATTTGGGTAGACGGCCACTTTTAAATAGACGGCGACATCTGTATTTAT  
 OL3  
 OL2  
 HincII  
 G  
 (-9G)  
 pL1  
 CCACTGCGCGGTGATACTGAGCACATCAGCAGGACGCACTGACCACCATGAAGGTGACGCTCTTAAAAATTAA  
 OL1  
 +1  
 -10  
 GGTGACGGCGCACTATGACTCGTGTAGTCGTCCTCGGTGACTGGTGGTACTTCCACTGCGAGAAATTTTAAATT  
 nutL  
 GCCCTGAAGAAGGCAGCATTCAAAGCAGAGGCTTTGGGGTGTGTGATACGAAACGAAGCATTGCC  
 CGGGACTTCTCCCGTCGTAAGTTTCGTCTTCCGAAACCCACACACTATGCTTTGCTTCGTAACCGG  
 BamHI

**FIG. 1B**



3 / 1 8




FIG. 5




FIG. 3






FIG. 2

RECTIFIED SHEET (RULE 91)

4 / 18



5 / 1 8





FIG. 6

FIG. 8

FIG. 10

RECTIFIED SHEET (RULE 91)




6 / 1 8

RECTIFIED SHEET (RULE 91)

FIG. 7A


7 / 18

**FIG. 7B**



8 / 1 8

FIG. 9A



9 / 1 8

RECTIFIED SHEET (RULE 91)

FIG. 9B

181 GACAGGATTAAATCGATGATTCGCCCGGGTTTGGGCGTATCAGTCGCCATGGTAAAT  
240 CTGTCCCTAAATTTTAGCTACTAAAGCGGGCCCAAACCCGCATAGTCAGCGGTACCATTT

241 GGAATGGGAATCCAGACGGGTGAAGCCTTCAAGTGCCGAACATAAATTGATGCGTTTGAT  
300 CCTTACCCCTTAGGTCTGCGCACTTCGGGAAGTTCACGGCTTGATTTTAACTACGCAAACTA

301 TCAAGCCAACCCGGCATTAAGTAAGCAGTTGATGGAATAGACTTTTATCCACTTTATTGC  
360 AGTTCGGTTGGGCCGTAATTTCATTCGTCAACTACCTTATCTGAAAATAGGTGAAAATAACG

M

→

361 TGTTACGGTCCTGATGACAGGACCGTTTCCCAACCGATTAAATCATAAATGAAAAATA  
420 ACAAATGCCAGGACTACTGTCCCTGGCAAAGGTTGGCTAAATTAGTATTATATACTTTTAT

RECTIFIED SHEET (RULE 91)

FIG. 11A



↓ M

**FIG. 11B**




FIG. 12

FIG. 14

1 3 / 1 8

181 GACAGGATTAAATCGATGATTTCGCCCGGGTTTGGCGGTATCAGTCGCCATGGTAA  
CTGTCCCTAATTTTAGCTACTAAAGCGGGCCCAAACCCGCATAGTCAGCGGTACCATTT 240

241 GGAATGGGAATCCAGACGCGTGAGCCCTTCAAGTGCCGAACTAAATTGATGCGTTTGAT  
CCTTACCCCTTAGGCTGCGCACTTCGGAAGTTCACGGCTTGATTTTAACTACGCAAACTA 300

301 TCAAGCCAACCCGGCATTAAGTAAGCAGTTGATGGAATAGACTTTTATCCACTTTATTGC  
AGTTCGGTTGGCCGTAATTCATTTCGTCAACTACCTTATCTGAAATAGGTGAATAACG 360

361 TGTTTACGGTCCTGATGACAGGACCGTTTTCCAACCGATTAAATCATAAATATGAAAAATA  
ACAAATGCCAGGACTACTGTCCCTGGCAAAGGTGGCTAATTAGTATTATATACTTTTTAT 420

*FIG. 13A*





FIG. 13B





15 / 18

FIG. 15



RECTIFIED SHEET (RULE 91)

16 / 18



RECTIFIED SHEET (RULE 91)

17/ 18

mRNA LEVEL




FIG. 17




FIG. 18A










FIG. 18B

18 / 18

PROMOTER FRAGMENT	$\beta$ -GALACTOSIDASE UNITS				mRNA LEVEL
	OVERNIGHT INCUBATION		TEMPORAL COLD SHOCK		
	37C	15C	37C	15C	
	5,950	35,730	3,620	8,890	(2.45) 2.8
	5,500	31,860	3,820	9,450	(2.5) 4.2
	2,970	28,170	2,240	8,890	(4.0) 2.5
	1,080	11,500	920	3,640	(4.0) 4.0
	4,180	17,030	1,840	4,920	(2.7) 3.2
	10,870	11,140	4,670	5,190	(1.1) 1.0
	2,260	47,520	2,040	14,880	(7.3) 10.0

RECTIFIED SHEET (RULE 91)

*F1*

FIG. 19

RECTIFIED SHEET (RULE 91)



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/08971

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12P 21/06

US CL : 435/69.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 320.1; 536/24.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	Proc. Natl. Acad. Sci. USA, Volume 92, Issued March 1995, Giladi et al., "Enhanced activity of the bacteriophage lambda pL promoter at low temperature", pages 2184-2188, see page 2188, lines 20-23.	36
X	Molecular Microbiology, Volume 11, issued March 1994, Lee et al., "Family of the major cold-shock protein, CspA (CS7.4), of Escherichia coli, whose members show a high sequence similarity with the eukaryotic Y-box binding proteins", pages 833-839, see pages 836-837.	1-6, 8, 10, 14-17, 24-27, 30-35

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T"	later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" documents defining the general state of the art which is not considered to be of particular relevance	"X"	documents of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier documents published on or after the international filing date	"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is used to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

16 OCTOBER 1995

Date of mailing of the international search report

15 NOV 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JUDITH S. BRUSCA

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/08971

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	FEBS Letters, Volume 271, issued October 1990, Shirano et al., "Low temperature cultivation of Escherichia coli carrying a rice lipoygenase L-2 cDNA produces a soluble and active enzyme at a high level", pages 128-130, see pages 128-129.	1-6, 34-35 ----- 7-39
Y	Journal of Bacteriology, Volume 174, issued June 1992, Tanabe et al., "Identification of the promoter region of the Escherichia coli major cold shock gene, cspA", pages 3867-3873, see pages 3869-3870.	8, 10, 14-17, 24-27, 30-33
Y	Journal of Molecular Biology, Volume 224, issued 1992, Giladi et al., "Supercoiling, integration host factor, and a dual promoter system, participate in the control of the bacteriophage lambda pL promoter", pages 937-948, see page 943.	8, 9, 11-13, 22, 23, 28, 29, 39
Y	Journal of Bacteriology, Volume 173, issued April 1991, Kulakauskas et al., "Efficient introduction of cloned mutant alleles into the Escherichia coli chromosome", pages 2633-2638, see page 2634.	7, 18, 19
Y	Journal of Biological Chemistry, Volume 256, issued February 1981, Horn et al., "The leftward promoter of bacteriophage lambda", pages 2003-2009, see page 2006.	8, 9, 11-13, 18, 22, 23, 28, 29